Nina V. Kopylova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nina V. Kopylova has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Yulia Desheva
Institute of Experimental Medicine
4 shared publications - Andrey Rekstin
Federal State Budgetary Scientific Institution “Institute of Experimental Medicine”, 197022 Saint Petersburg, Russia
3 shared publications - Daniil D. Sokolovskiy
Institute of Experimental Medicine
3 shared publications - Danila Sergeevich Guzenkov
Institute of Experimental Medicine
3 shared publications - Daria S. Petrachkova
Federal State Budgetary Scientific Institution “Institute of Experimental Medicine”, 197022 Saint Petersburg, Russia
3 shared publications - Irina V. Mayorova
Federal State Budgetary Scientific Institution “Institute of Experimental Medicine”, 197022 Saint Petersburg, Russia; Saint Petersburg State University, 199034 Saint Petersburg, Russia
3 shared publications
Latest Publications
- Open Access
- 15 November 2026
- Published by Central Research Institute for Epidemiology in Journal of microbiology, epidemiology and immunobiology
- Vol. 103 (5) , 680-693
Study of Humoral Immunity against Two Antigenic Lines of Influenza B Virus in Different Age Groups
Introduction. Antibodies to hemagglutinin (HA) and neuraminidase (NA) help neutralize the virus, but the high variability of HA limits their effectiveness. Meanwhile, antibodies to NA reduce replication and provide cross-immunity, making NA a promising target antigen for vaccine development. The aim of the research was conducting a phylogenetic analysis of influenza B viruses and assessing the specificity of antibodies to HA and NA of the B/Yamagata and B/Victoria viruses in the blood of patients depending on their age. Materials and methods. A phylogenetic analysis of the sequences encoding HA and NA of influenza B/Victoria and B/Yamagata viruses was carried out, and the specificity of antibodies in 145 blood plasma samples from patients of different ages examined in 2023 was assessed in relation to HA and NA of these lineages. Results. Phylogenetic analysis revealed heterogeneity in the NA of B/Victoria lineage viruses, including viruses with an NA structure similar to the B/Yamagata lineage. Among patients aged 18–59 years examined in 2023, higher titers of antibodies to HA and NA of the B/Yamagata lineage were detected compared to B/Victoria. Protective titers of antibodies to HA were absent in the majority of patients of all age groups, while seropositive titers of antibodies to NA were detected in 39–65% of those examined. Conclusion. The higher frequency of detection of antibodies to NA compared to antibodies to HA may indicate a longer duration of NA-specific immunity. NA of influenza B viruses is a promising target for the development of vaccines with a broad spectrum of protection.
- 15 November 2026
- Published by Central Research Institute for Epidemiology in Journal of microbiology, epidemiology and immunobiology
- Vol. 103 (5) , 680-693
Open AccessStudy of Humoral Immunity against Two Antigenic Lines of Influenza B Virus in Different Age Groups
Introduction. Antibodies to hemagglutinin (HA) and neuraminidase (NA) help neutralize the virus, but the high variability of HA limits their effectiveness. Meanwhile, antibodies to NA reduce replication and provide cross-immunity, making NA a promising target antigen for vaccine development. The aim of the research was conducting a phylogenetic analysis of influenza B viruses and assessing the specificity of antibodies to HA and NA of the B/Yamagata and B/Victoria viruses in the blood of patients depending on their age. Materials and methods. A phylogenetic analysis of the sequences encoding HA and NA of influenza B/Victoria and B/Yamagata viruses was carried out, and the specificity of antibodies in 145 blood plasma samples from patients of different ages examined in 2023 was assessed in relation to HA and NA of these lineages. Results. Phylogenetic analysis revealed heterogeneity in the NA of B/Victoria lineage viruses, including viruses with an NA structure similar to the B/Yamagata lineage. Among patients aged 18–59 years examined in 2023, higher titers of antibodies to HA and NA of the B/Yamagata lineage were detected compared to B/Victoria. Protective titers of antibodies to HA were absent in the majority of patients of all age groups, while seropositive titers of antibodies to NA were detected in 39–65% of those examined. Conclusion. The higher frequency of detection of antibodies to NA compared to antibodies to HA may indicate a longer duration of NA-specific immunity. NA of influenza B viruses is a promising target for the development of vaccines with a broad spectrum of protection.
- Open Access
- 28 November 2025
- Published by Open Exploration Publishing in Exploration of Immunology
- Vol. 5, 1003230
Recombinant influenza A/H1N1pdm09 vaccine expressing streptococcal surface epitope for dual protection
Aim: Develop A/H1N1pdm09-based live attenuated influenza vaccines (LAIVs) presenting chimeric hemagglutinin (HA) fused to fragments of Streptococcus pneumoniae (PspA, Spr1875) or S. agalactiae (ScaAB) to elicit combined anti-influenza and anti-bacterial immunity. Methods: Recombinant LAIVs were generated by reverse genetics. Replicative fitness was measured in embryonated chicken eggs (CE; log10 EID50/0.1 mL, n = 5 per delution) and MDCK cells (log10 TCID50/mL, n = 5). BALB/c mice (n = 20 per group; serology n = 6 per group; lung titers n = 5 per group) received intranasal 106 EID50. Systemic IgG and mucosal IgA to influenza and to the recombinant pneumococcal peptide were quantified by ELISA (GMT ± SD). Early cytokine responses were profiled in THP-1 cells. Results: All recombinant strains replicated in CE at 33°C but were temperature-sensitive at 39°C. H1-ScaAB retained relatively high replication and exhibited a cold-adapted phenotype despite a large N-terminal insert. In MDCK cells, H1-PspA showed significantly reduced replication compared with the parental LAIV. In mouse lungs, replication on day 3 post-immunization was significantly lower for H1-ScaAB and H1-PspA compared with the parental LAIV strain (p < 0.05). The parental LAIV induced robust systemic anti-influenza IgG and, uniquely for H1-ScaAB, significant mucosal anti-influenza IgA (p < 0.05). H1-Spr generated stronger antibody responses to the inserted pneumococcal peptide (p < 0.05). THP-1 assays revealed construct-specific cytokine patterns (unmodified H1N1: highest IFN-α; H1-Spr: elevated IL-6; H1-ScaAB: greatest MCP-1). Conclusions: Multiple A/H1N1pdm09-based recombinant LAIVs with chimeric HA can replicate in eggs and murine respiratory tract and induce dual influenza/pneumococcal antigen responses. Expanded biophysical validation, functional antibody assays and challenge studies are needed to optimize insert design without compromising viral fitness.
- 28 November 2025
- Published by Open Exploration Publishing in Exploration of Immunology
- Vol. 5, 1003230
Open AccessRecombinant influenza A/H1N1pdm09 vaccine expressing streptococcal surface epitope for dual protection
Aim: Develop A/H1N1pdm09-based live attenuated influenza vaccines (LAIVs) presenting chimeric hemagglutinin (HA) fused to fragments of Streptococcus pneumoniae (PspA, Spr1875) or S. agalactiae (ScaAB) to elicit combined anti-influenza and anti-bacterial immunity. Methods: Recombinant LAIVs were generated by reverse genetics. Replicative fitness was measured in embryonated chicken eggs (CE; log10 EID50/0.1 mL, n = 5 per delution) and MDCK cells (log10 TCID50/mL, n = 5). BALB/c mice (n = 20 per group; serology n = 6 per group; lung titers n = 5 per group) received intranasal 106 EID50. Systemic IgG and mucosal IgA to influenza and to the recombinant pneumococcal peptide were quantified by ELISA (GMT ± SD). Early cytokine responses were profiled in THP-1 cells. Results: All recombinant strains replicated in CE at 33°C but were temperature-sensitive at 39°C. H1-ScaAB retained relatively high replication and exhibited a cold-adapted phenotype despite a large N-terminal insert. In MDCK cells, H1-PspA showed significantly reduced replication compared with the parental LAIV. In mouse lungs, replication on day 3 post-immunization was significantly lower for H1-ScaAB and H1-PspA compared with the parental LAIV strain (p < 0.05). The parental LAIV induced robust systemic anti-influenza IgG and, uniquely for H1-ScaAB, significant mucosal anti-influenza IgA (p < 0.05). H1-Spr generated stronger antibody responses to the inserted pneumococcal peptide (p < 0.05). THP-1 assays revealed construct-specific cytokine patterns (unmodified H1N1: highest IFN-α; H1-Spr: elevated IL-6; H1-ScaAB: greatest MCP-1). Conclusions: Multiple A/H1N1pdm09-based recombinant LAIVs with chimeric HA can replicate in eggs and murine respiratory tract and induce dual influenza/pneumococcal antigen responses. Expanded biophysical validation, functional antibody assays and challenge studies are needed to optimize insert design without compromising viral fitness.
- 25 December 2024
- Published by ECO-Vector LLC in Medical academic journal
- Vol. 24 (4) , 41-50
Biological properties of the recombinant influenza A/H1N1pdm09 virus expressing a fragment of the Streptococcus pneumoniae surface protein
BACKGROUND: Live influenza vaccine strains may serve as a promising system for the delivery of target antigens to the body because such a vaccine is administered intranasally and stimulates multiple chains of immunity against both the target pathogen and the influenza virus, a serious infection that causes significant socioeconomic damage worldwide each year. AIM: The study was aimed to evaluate the biological properties of a recombinant live influenza vaccine strain of subtype A/H1N1pdm09 expressing a fragment of the Streptococcus pneumoniae Spr1875 surface protein. MATERIALS AND METHODS: The A/H1N1pdm09 recombinant live influenza vaccine strain expressing a 69-amino-acid fragment of the S. pneumoniae surface protein Spr1875 as part of a chimeric hemagglutinin molecule was prepared by reverse genetics using an 8-plasmid system. The reproductive activity of the recombinant virus was studied in chicken embryos, whereas immunogenicity and protective efficiency were studied in Balb/C mice. RESULTS: The recombinant influenza virus strain with hemagglutinin H1-Spr-69 demonstrated active reproduction in chicken embryos and retained the temperature-sensitive phenotypic trait of vaccine viruses. However, its growth in the respiratory tract of mice was limited compared with the original A/H1N1pdm09 vaccine virus. Intranasal administration of the recombinant H1-Spr strain to mice resulted in stimulation of virus-specific serum IgG antibody production comparable to that induced by the classic live influenza A/H1N1pdm09 vaccine. Furthermore, this strain induced an increase in IgG antibodies against the pneumococcal insertion Spr1875. Although the A/H1N1pdm09 variant was more effective than the chimeric H1-Spr virus in preventing weight loss in mice infected with mouse-adapted influenza A/California/07/09 (H1N1)pdm09 (H1N1)pdm09 virus, the titers of the challenge virus in the lungs of mice from both vaccine groups were significantly reduced compared with unvaccinated animals. CONCLUSIONS: The results demonstrate the ability of the chimeric recombinant H1-Spr strain to stimulate protective immunity against influenza virus.
- 25 December 2024
- Published by ECO-Vector LLC in Medical academic journal
- Vol. 24 (4) , 41-50
Biological properties of the recombinant influenza A/H1N1pdm09 virus expressing a fragment of the Streptococcus pneumoniae surface protein
BACKGROUND: Live influenza vaccine strains may serve as a promising system for the delivery of target antigens to the body because such a vaccine is administered intranasally and stimulates multiple chains of immunity against both the target pathogen and the influenza virus, a serious infection that causes significant socioeconomic damage worldwide each year. AIM: The study was aimed to evaluate the biological properties of a recombinant live influenza vaccine strain of subtype A/H1N1pdm09 expressing a fragment of the Streptococcus pneumoniae Spr1875 surface protein. MATERIALS AND METHODS: The A/H1N1pdm09 recombinant live influenza vaccine strain expressing a 69-amino-acid fragment of the S. pneumoniae surface protein Spr1875 as part of a chimeric hemagglutinin molecule was prepared by reverse genetics using an 8-plasmid system. The reproductive activity of the recombinant virus was studied in chicken embryos, whereas immunogenicity and protective efficiency were studied in Balb/C mice. RESULTS: The recombinant influenza virus strain with hemagglutinin H1-Spr-69 demonstrated active reproduction in chicken embryos and retained the temperature-sensitive phenotypic trait of vaccine viruses. However, its growth in the respiratory tract of mice was limited compared with the original A/H1N1pdm09 vaccine virus. Intranasal administration of the recombinant H1-Spr strain to mice resulted in stimulation of virus-specific serum IgG antibody production comparable to that induced by the classic live influenza A/H1N1pdm09 vaccine. Furthermore, this strain induced an increase in IgG antibodies against the pneumococcal insertion Spr1875. Although the A/H1N1pdm09 variant was more effective than the chimeric H1-Spr virus in preventing weight loss in mice infected with mouse-adapted influenza A/California/07/09 (H1N1)pdm09 (H1N1)pdm09 virus, the titers of the challenge virus in the lungs of mice from both vaccine groups were significantly reduced compared with unvaccinated animals. CONCLUSIONS: The results demonstrate the ability of the chimeric recombinant H1-Spr strain to stimulate protective immunity against influenza virus.
- Open Access
- 24 December 2024
- Published by ECO-Vector LLC in Medical academic journal
- Vol. 24 (3) , 126-132
Experimental study of early protective action of live influenza vaccine against heterologous influenza infection
BACKGROUND: The live influenza vaccine is an effective means of combating influenza infection. It is characterized by ease of administration, cost-effectiveness, and rapid production, and it stimulates both systemic and local immune responses. This study investigates early protection against heterologous influenza infection within one week after immunization with the live influenza vaccine. AIM: The aim of the study was to experimentally investigate the mechanisms of early protection against heterologous influenza infection following immunization with a live influenza vaccine. MATERIALS AND METHODS: In in vitro experiments, we studied the production of type I interferons in a culture of monocyte-macrophage-derived cells using enzyme-linked immunosorbent assay. THP-1 cells were seeded at a concentration of 3 × 106 cells/ml, and after 48 hours, the vaccine strain of the live influenza vaccine was added. Mice were immunized intranasally under light ether anesthesia with the vaccine virus A/17/South Africa/2013/01(H1N1)pdm09, obtained from the virus collection of the Virology Department of the Institute of Experimental Medicine, at a dose of 6.0 lg EID50. Infection was performed on the 6th day after immunization with the virus A/Indonesia/5/2005(H5N1) IDCDC-RG2. RESULTS: During the introduction of both the vaccine virus and the parental virus A/South Africa/3626/2013 (H1N1)pdm09 into THP-1 cell cultures, an increase in the production of early cytokines was observed. Immunization with the live influenza vaccine completely protected the mice from lethal infection with a heterologous influenza virus. CONCLUSIONS: The obtained data may indicate the benefits of using the live influenza vaccine during the seasonal uptick of acute respiratory viral infections due to the stimulation of innate immune factors.
- 24 December 2024
- Published by ECO-Vector LLC in Medical academic journal
- Vol. 24 (3) , 126-132
Open AccessExperimental study of early protective action of live influenza vaccine against heterologous influenza infection
BACKGROUND: The live influenza vaccine is an effective means of combating influenza infection. It is characterized by ease of administration, cost-effectiveness, and rapid production, and it stimulates both systemic and local immune responses. This study investigates early protection against heterologous influenza infection within one week after immunization with the live influenza vaccine. AIM: The aim of the study was to experimentally investigate the mechanisms of early protection against heterologous influenza infection following immunization with a live influenza vaccine. MATERIALS AND METHODS: In in vitro experiments, we studied the production of type I interferons in a culture of monocyte-macrophage-derived cells using enzyme-linked immunosorbent assay. THP-1 cells were seeded at a concentration of 3 × 106 cells/ml, and after 48 hours, the vaccine strain of the live influenza vaccine was added. Mice were immunized intranasally under light ether anesthesia with the vaccine virus A/17/South Africa/2013/01(H1N1)pdm09, obtained from the virus collection of the Virology Department of the Institute of Experimental Medicine, at a dose of 6.0 lg EID50. Infection was performed on the 6th day after immunization with the virus A/Indonesia/5/2005(H5N1) IDCDC-RG2. RESULTS: During the introduction of both the vaccine virus and the parental virus A/South Africa/3626/2013 (H1N1)pdm09 into THP-1 cell cultures, an increase in the production of early cytokines was observed. Immunization with the live influenza vaccine completely protected the mice from lethal infection with a heterologous influenza virus. CONCLUSIONS: The obtained data may indicate the benefits of using the live influenza vaccine during the seasonal uptick of acute respiratory viral infections due to the stimulation of innate immune factors.
- 1 January 2019
- Published by Pleiades Publishing Ltd in Biochemistry (Moscow), Supplement Series A: Membrane and Cell Biology
- Vol. 13 (1) , 78-84
Depression of the Evoked Quantal Acetylcholine Secretion in Frog Neuromuscular Junction by Phospholipases A2 from the Venom of Steppe Viper Vipera ursiniirenardi
In this work we studied the influence of phospholipase A2 vurtoxin and its homologue lacking enzymatic activity (Vur-S49), isolated from the venom of steppe viper Vipera ursinii renardi, on...
- 1 January 2019
- Published by Pleiades Publishing Ltd in Biochemistry (Moscow), Supplement Series A: Membrane and Cell Biology
- Vol. 13 (1) , 78-84
Depression of the Evoked Quantal Acetylcholine Secretion in Frog Neuromuscular Junction by Phospholipases A2 from the Venom of Steppe Viper Vipera ursiniirenardi
In this work we studied the influence of phospholipase A2 vurtoxin and its homologue lacking enzymatic activity (Vur-S49), isolated from the venom of steppe viper Vipera ursinii renardi, on...